Heart Valve Disease Awareness Survey 2017: what did we achieve since 2015?
The 2015 Heart Valve Disease Awareness Survey showed a low knowledge and awareness about heart valve disease in the general population despite its high prevalence and morbidity. The 2017 survey was conducted to re-evaluate concern and knowledge about heart valve disease after 2 years of rapidly increasing patient numbers presenting with heart valve disease.
Methods and results
A total of 12,820 people aged 60 years or older in 11 European countries took part in the survey. While the number of people concerned most about heart valve disease increased significantly (2015:1.7% vs. 2017:2.1%; p < 0.001), it is still very low compared to cancer (28.8%) or Alzheimer’s disease (20.9%). More people claim to be familiar with heart valve disease in general (2015: 17.1% vs. 2017: 20.0%; p < 0.001) and the majority claims to know of at least one therapy for heart valve disease (61.9%). Nevertheless, only 3.8% could correctly identify aortic stenosis (AS), which is significantly less than in 2015 (7.2%; p < 0.001). As before, the majority of the respondents claimed to rarely or never undergo a stethoscope check from their general practitioner (2015: 54.2% vs. 2017: 50.6%, p < 0.001); nevertheless, a positive trend can be seen. People wish heart valve disease to be part of regular checks by the general practitioners.
The general population’s knowledge of heart valve disease in general slightly increased over the last 2 years. However, detailed understanding of aortic stenosis and its treatment options is still low, as is the level of concern shown for heart valve disease. Nevertheless, the general population cites heart valve disease as a condition they wish to be checked for regularly.
KeywordsHeart valve disease Survey Knowledge Awareness Aortic stenosis
The 2017 Heart Valve Disease Awareness Survey was conducted by Censuswide and funded by Edwards Lifesciences.
Compliance with ethical standards
Conflict of interest
L. Gaede is a consultant for Abbott vascular and Edwards Lifesciences. H. Möllmann has received speaker’s honoraria from Edwards Lifesciences, and proctor and speaker’s honoraria from Abbott and Medtronic. G. J. Brandon Bravo Bruinsma is a consultant for Edwards Lifesciences and CEC member for LivaNova. J. Zamorano has received research grants from Edwards Lifesciences. L. Aarberge has been a proctor for Edwards Lifesciences. The other authors have no conflicts of interest to declare.
- 4.Lancellotti P, Troisfontaines P, Toussaint AC, Pierard LA (2003) Prognostic importance of exercise-induced changes in mitral regurgitation in patients with chronic ischemic left ventricular dysfunction. Circulation 108:1713–1717. https://doi.org/10.1161/01.CIR.0000087599.49332.05 CrossRefPubMedGoogle Scholar
- 9.Baumgartner H, Falk V, Bax JJ et al (2017) 2017 ESC/EACTS guidelines for the management of valvular heart disease The Task Force for the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European. Eur Heart J 38:2739–2791. https://doi.org/10.1093/eurheartj/ehx391 CrossRefPubMedGoogle Scholar
- 13.Möllmann H (2015) In-hospital outcome of transcatheter vs. surgical aortic valve replacement in patients with aortic valve stenosis (AQUA Registry). Clin Res Cardiol 104:1934Google Scholar
- 17.Puls M, Lubos E, Boekstegers P et al (2016) One-year outcomes and predictors of mortality after MitraClip therapy in contemporary clinical practice: results from the German transcatheter mitral valve interventions registry. Eur Heart J 37:703–712. https://doi.org/10.1093/eurheartj/ehv627 CrossRefPubMedGoogle Scholar
- 19.Frerker C, Bestehorn K, Schlüter M et al (2017) In-hospital mortality in propensity-score matched low-risk patients undergoing routine isolated surgical or transfemoral transcatheter aortic valve replacement in 2014 in Germany. Clin Res Cardiol 106:610–617. https://doi.org/10.1007/s00392-017-1097-y CrossRefPubMedGoogle Scholar
- 24.Bleiziffer S, Bosmans J, Brecker S et al (2017) Erratum to: Insights on mid-term TAVR performance: 3-year clinical and echocardiographic results from the CoreValve ADVANCE study (Clin Res Cardiol, 10.1007/s00392-017-1120-3). Clin Res Cardiol 106:849. https://doi.org/10.1007/s00392-017-1124-z CrossRefPubMedGoogle Scholar